|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Post Graduate Education Course of the XX11 Congress of the Transplant Society Incorporating the 32nd Annual Scientific Meeting of the Australasian and South East Asian Tissue Typing Association (ASEATTA) –Saturday August 9th,2008
HLA Antibody Identification in the 21st Century –Laboratory and Clinical Aspects
Session 1: 8.30-10.00 Chairs: Frank Christiansen( Perth) ,Heather Dunckley (Sydney)8.30-8.40 Welcome and Introduction 8.40- 9.00 Ron Kerman , University of Texas Medical School, Houston ,Texas Transplantation Histocompatibility Conference Report ( Chicago, March 2008). 9.00-9.20 Ron Kerman ,University of Texas medical School, Houston, Texas Are all antibodies bad? 9.20- 10.00 Frans Claas ,Leiden University Medical Centre ,Leiden Acceptable and non-acceptable HLA mismatches and antibodies
10.00 -10.30 Morning Tea
Session 2 :10.30-12.30 Chairs: Rhonda Holdsworth (Melbourne) , Narelle Watson (Sydney)10-30- 10.55 Peter Nickerson, University of Manitoba Strategies for transplanting highly sensitised patients in Canada
10.55- 11.35 Ron Kerman ,University of Texas Medical School, Houston Using MFI to correlate crossmatch results and antibody titration. 11.35-12.15 Howard Gebel, Emory University Hospital,Atlanta The pros and cons of virtual crossmatching.
12.15- 12.30 General discussion of morning presentations 12.30- 1.30 Lunch
Session 3 1.30- 3.00 Chairs: Greg Bennett (Adelaide) , Paul Dunn (Auckland)
Andrea Zachary, John Hopkins University School of Medicine, Baltimore
The impact of persistent low level donor specific antibody (DSA) following de-sensitisation.
Sue Lefell , John Hopkins University School of Medicine, Baltimore
Do patients with low level donor specific antibody (DSA) need de-sensitisation? 2.50-3.00 General Discussion
3.00-3.30 Afternoon Tea
Session 4 3.30-5.30 Chairs: Frank Christiansen (Perth), Brian Tait (Melbourne) This will be an interactive session consisting of brief case presentations (maximum 7 minutes each) followed by a panel discussion and questions from the audience. 5.30-5.40 Summary and closure of meeting.
|